Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade®) versus deferoxamine in patients with β-thalassemia and transfusional hemosiderosis

被引：9

作者：

Cappellini, M

Bejaoui, M

Perrotta, S

Agaoglu, L

Kattamis, A

Giardina, P

Janka-Schaub, G

Opitz, H

Ressayre-Djaffer, C

Alberti, D

机构：

[1] Univ Milan, IRCCS, Osped Policlin, I-20122 Milan, Italy

[2] Ctr Natl Greffes Moelle Osseuse, Tunis, Tunisia

[3] Univ Naples, Dept Pediat, I-80138 Naples, Italy

[4] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey

[5] Univ Athens, Agia Sofia Childrens Hosp, Athens, Greece

[6] Weill Med Coll, Div Pediat Hematol, New York, NY USA

[7] Univ Krankenhaus Eppendorf, Poliklinikum, Hamburg, Germany

[8] Novartis, Basel, Switzerland

来源：

关键词：

D O I：

10.1182/blood.V104.11.3619.3619

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3619

引用

页码：984A / 984A

页数：1